Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man - PubMed (original) (raw)
Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man
S Ueda et al. Hypertension. 2000 Apr.
Abstract
Angiotensin-(1-7) has been suggested to be a novel vasodilating peptide. We investigated the direct vascular effect of angiotensin-(1-7) in human forearm resistant vessels, particularly with regard to the interaction with angiotensin II, in healthy normotensive men by strain-gauge venous occlusion plethysmography with intra-arterial infusions of peptides. Intra-arterial infusion of angiotensin-(1-7) at 0.1 to 2000 pmol/min did not cause vasodilatation but rather reduced forearm blood flow by approximately 10% at the highest dose. A placebo-controlled study showed that angiotensin-(1-7) at 0.5 to 40 nmol/min caused weak but significant vasoconstriction (P=0.0016 by ANOVA). Angiotensin-(1-7) at 100 pmol/min, but not at 10 pmol/min, significantly shifted the angiotensin II dose-response curve toward the right (mean+/-SD of percent changes in forearm blood flow: -19+/-17%, -33+/-22%, -55+/-12%, -63+/-10%, and -68+/-5% at 5, 10, 25, 50, and 100 pmol/min of angiotensin II, respectively, with saline; 5+/-13%, 0. 9+/-18%, -40+/-16%, -54+/-9%, and -61+/-6% with angiotensin-(1-7), P=0.0021 by ANOVA). Angiotensin-(1-7) did not affect the dose-response curve of noradrenaline [3+/-12%, 5+/-16%, -20+/-22%, -31+/-18%, and -40+/-12% at 25, 50, 100, 300, and 600 pmol/min of noradrenaline, respectively, with saline; -4+/-15%, -2+/-23%, -29+/-22%, -34+/-16%, and -42+/-9% with angiotensin-(1-7)]. Our results suggest that angiotensin-(1-7) antagonizes vasoconstriction by angiotensin II in human resistant vessels and might act as an endogenous angiotensin II antagonist.
Similar articles
- Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man.
Ueda S, Masumori-Maemoto S, Wada A, Ishii M, Brosnihan KB, Umemura S. Ueda S, et al. J Hypertens. 2001 Nov;19(11):2001-9. doi: 10.1097/00004872-200111000-00010. J Hypertens. 2001. PMID: 11677365 Clinical Trial. - Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man.
Newby DE, Masumori S, Johnston NR, Boon NA, Webb DJ. Newby DE, et al. Cardiovasc Res. 1997 Nov;36(2):268-75. doi: 10.1016/s0008-6363(97)00171-5. Cardiovasc Res. 1997. PMID: 9463638 Clinical Trial. - Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients.
Sim JS, Dick JB, Struthers AD. Sim JS, et al. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):109-13. doi: 10.3317/jraas.2004.026. J Renin Angiotensin Aldosterone Syst. 2004. PMID: 15526245 Clinical Trial. - Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo.
Dijkhorst-Oei LT, Stroes ES, Koomans HA, Rabelink TJ. Dijkhorst-Oei LT, et al. J Cardiovasc Pharmacol. 1999 Mar;33(3):420-4. doi: 10.1097/00005344-199903000-00012. J Cardiovasc Pharmacol. 1999. PMID: 10069678 Clinical Trial. - Chemical modification of tumour blood flow.
Jirtle RL. Jirtle RL. Int J Hyperthermia. 1988 Jul-Aug;4(4):355-71. doi: 10.3109/02656738809016490. Int J Hyperthermia. 1988. PMID: 3290350 Review.
Cited by
- Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration.
Zhang F, Hu Y, Xu Q, Ye S. Zhang F, et al. PLoS One. 2010 Aug 23;5(8):e12323. doi: 10.1371/journal.pone.0012323. PLoS One. 2010. PMID: 20808802 Free PMC article. - ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease.
Kuriakose J, Montezano AC, Touyz RM. Kuriakose J, et al. Clin Sci (Lond). 2021 Jan 29;135(2):387-407. doi: 10.1042/CS20200480. Clin Sci (Lond). 2021. PMID: 33511992 Free PMC article. Review. - A systematic review to investigate whether Angiotensin-(1-7) is a promising therapeutic target in human heart failure.
Lee VC, Lloyd EN, Dearden HC, Wong K. Lee VC, et al. Int J Pept. 2013;2013:260346. doi: 10.1155/2013/260346. Epub 2013 Dec 12. Int J Pept. 2013. PMID: 24454410 Free PMC article. Review. - The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.
Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. Borém LMA, et al. Hypertens Res. 2018 Jun;41(6):394-405. doi: 10.1038/s41440-018-0040-6. Epub 2018 Apr 10. Hypertens Res. 2018. PMID: 29636553 Free PMC article. Review. - Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic.
Chen H, Peng J, Wang T, Wen J, Chen S, Huang Y, Zhang Y. Chen H, et al. Biochem Pharmacol. 2023 Feb;208:115370. doi: 10.1016/j.bcp.2022.115370. Epub 2022 Dec 5. Biochem Pharmacol. 2023. PMID: 36481346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources